



Company Presentation

Annual General Meeting






John Walstab
CEO and Managing Director

Overview & Focus

Company Overview

ParagonCare

ParagonCare Brands



DESIGNS FOR VISION



REM SYSTEMS



SCANMEDICS



surgical
specialties



Specialist
Medical
Supplies

TOTAL
COMMUNICATIONS

LabGear



Immuno

Quantum

immulab 

ParagonCare

- Established 2008 in Australia
- Medical Equipment Distribution & Manufacturing
- Operating across Eye Care, Orthopaedics, Surgical, Neonatal, Critical Care, Laboratory, Radiology, Oncology, Aesthetics and Immunohaematology markets
- Merging with Quantum Health Group in early 2022 provided a gateway to Asian markets and expanded OEM opportunities
- Currently re-branding to move ParagonCare from a house of brands to a Masterbrand.

Strong Asia Pacific Reach

ParagonCare

625
employees

ASIA
180

AUS
384

NZ
61

8
countries
across
Asia Pacific

- Broad Geographical reach
 - Australia
 - Korea
 - Japan
 - Vietnam
 - New Zealand
 - Philippines
 - Thailand
 - China
- Strong presence in Asia Pacific
 - organic growth
 - enhancement of value proposition for suppliers
 - increasing scale and efficiency
- Further expansion in Asia
 - Singapore, Malaysia and Indonesia
- Building Asia support teams within ParagonCare

A comprehensive distribution solution for global suppliers (OEMs)

Addressing challenges for global suppliers

- Local Market Knowledge
- Business Scale Differences
- Transparency & Trust
- Regulatory Complexity / Compliance
- Brand Integrity
- Logistics Complexity
- Service Quality & Consistency
- Governance Risks



Customer Portfolio

Institutions

- Public / Private Hospitals
- Laboratories
- Government Agencies
- Medical Research
- Industry
- Universities

Modalities

- Aged Care
- Aesthetics
- Anaesthetists
- Audiology
- Biotechnology
- Critical Care
- Environmental
- ICU
- Molecular Imaging
- Obstetrics
- Ophthalmologists
- Optometrists
- Orthopaedics
- Paediatrics
- Pathology
- Radiology
- Ultrasound
- Veterinary

ParagonCare

CLASSYS
Technology for better life

MEDLINE

Iba

CIVCO

Axonics

bonraybio

MEDICAL

Carestream

HOYA

UNITED IMAGING

B|BRAUN

IMMUCOR

ACCURAY

PHILIPS

icare

EQUASHIELD®
Compounding Technologies

MicroPort

Viveca
Biomed

CONMED
CORPORATION

CODAN

SAMSUNG

Duress™

New Mount Waverley facility will support the Immulab export opportunity

Commissioned to support an uplift in Immulab manufacturing capacity and to facilitate consolidation of all Victorian operations onto one site.

- Majority of the Victorian ParagonCare teams are now operating from the new facility
- Mount Waverley is a cornerstone investment for the ParagonCare Group as it forms a critical part of our longer-term growth strategy which includes international markets
- We are progressing well towards completion of works with key project activities remaining on schedule, with TGA accreditation for the manufacturing facility expected in early to mid 2024.



Overview of FY23 results

\$308m

Sales revenue*

^ 29% pcp

Mainly reflects the inclusion of Quantum and SMS.

\$38.4m

Underlying EBITDA

^ 35% pcp

Mainly reflects the inclusion of Quantum and SMS.
Like for like organic growth of around 10% in FY23.

\$15.6m

Underlying Net Profit[#]

^ 61% pcp

Includes impact of higher amortisation charges ex Quantum acquisition and SaaS.

8.5%

Underlying ROIC[#]

FY23 8.5% vs 1H 8.7% (12 month trailing).

0.6¢

Per share final dividend (fully franked)

Represents a 43% payout ratio of Underlying NPAT.
Last 12 months dividends (1.2cps) equates to a fully franked yield above 7%[#].
DRP reinstated to support capex requirements.

\$64M

Net Debt (excluding AASB16)

Debt has decreased by \$6m since December 2022.
Increase since June 2022 mainly reflects cash portion of SMS acquisition.
Net Debt 1.9 times Underlying EBITDA (Excl AASB16).

* Excludes Lovell discontinued operation

Based on share price of \$0.22

Overview and Highlights

- 
- Continued strong performance in Asia
 - SMS integration complete and business performing above expectations
 - Refinanced – NAB and HSBC
 - Progress on introduction of ophthalmic products into Asia and medical imaging into ANZ
 - Installation of IBA Cyclotron in WA
 - Commenced operations of both ParagonCare Japan and Vietnam
 - Discontinued operations – Lovell Surgical Supplies
 - Identifying new partnerships in healthcare AI and Robotics
 - Establishment of key partnerships with key suppliers. Including Samsung, United Imaging, Dures, Civco, Equashield, Axonics, B.Braun, Bonracybio and Viveca.

Education Hub

Opened in New Zealand on the 18 October 2023, presenting the latest in healthcare technology innovation in a simulated 'real world' environment.

Designed to provide a hands-on, interactive learning experience and innovative educational programs for all involved in the delivery of healthcare solutions.


The digitally integrated OR and ICU showcases the latest technologies in the operating environment, including:

- Modular glass
- Clean room
- Continuous visible light disinfection
- Patient lifts
- Latest technologies in Intraoperative ultrasound, robotic-assisted surgery, 4K visualisation

Built in conjunction with Australian partner, Wilhelm Integrated Solutions.




Focus on Efficient Growth



Focus

Reduction in corporate costs
Efficient organic growth
Consolidation of ERPs
Unified ParagonCare branding
Consolidation of operations
Manage by distribution partner
Simplified business structure
Clearer market communication



Organic growth

- based on strategic plans
- supported by improved execution



M & A growth

- tightly aligned to strategy
- efficiently integrated

Outlook

Corporate Review

- A full cost reduction and business innovation review
- A leaner, contemporary management structure
- Disciplined inventory and cash management
- Continuing current growth initiatives with a focus on efficient organic growth
- Smaller strategic acquisitions will be explored where efficient integration is possible
- Management will focus on individual Supplier (OEM) performance.

Earnings Outlook

- YTD we are currently tracking ahead of our prior year results and will be in a better position to give more guidance after the corporate review and half-year close
- Beyond FY23, we expect to have accelerated growth beyond 10% per annum, excluding any acquisitions.



Q&A

(Company Presentation)

Annual General Meeting 2023

Thank you for joining us today

ParagonCare